北京大学学报（医学版） ›› 2023, Vol. 55 ›› Issue (5): 775-780. doi: 10.19723/j.issn.1671-167X.2023.05.002
前列腺癌新辅助治疗与辅助治疗的现状及进展
薛蔚*(
),董樑,钱宏阳,费笑晨
- 上海交通大学医学院附属仁济医院泌尿外科, 上海 200127
蔚 薛*(),樑 董,宏阳 钱,笑晨 费
中图分类号:
- R737.25
| 1 |
ChenR , RenS , Chinese Prostate Cancer Consortium ,et al.Prostate cancer in Asia: A collaborative report[J].Asian J Urol,2014,1(1):15-29.
doi: 10.1016/j.ajur.2014.08.007 |
| 2 |
ManoR , EasthamJ , YossepowitchO .The very-high-risk prostate cancer: A contemporary update[J].Prostate Cancer Prostatic Dis,2016,19(4):340-348.
doi: 10.1038/pcan.2016.40 |
| 3 |
ShelleyMD , KumarS , WiltT ,et al.A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma[J].Cancer Treat Rev,2009,35(1):9-17.
doi: 10.1016/j.ctrv.2008.08.002 |
| 4 | KumarS , ShelleyM , HarrisonC ,et al.Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer[J].Cochrane Database Syst Rev,2006,(4):CD006019. |
| 5 |
O'DonnellA , JudsonI , DowsettM ,et al.Hormonal impact of the 17alpha-hydroxylase/C(17, 20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer[J].Br J Cancer,2004,90(12):2317-2325.
doi: 10.1038/sj.bjc.6601879 |
| 6 |
TaplinME , MontgomeryB , LogothetisCJ ,et al.Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: Results of a randomized phase Ⅱ neoadjuvant study[J].J Clin Oncol,2014,32(33):3705-3715.
doi: 10.1200/JCO.2013.53.4578 |
| 7 |
EfstathiouE , DavisJW , PistersL ,et al.Clinical and biological characterisation of localised high-risk prostate cancer: Results of a randomised preoperative study of a luteinising hormone-releasing hormone agonist with or without abiraterone acetate plus prednisone[J].Eur Urol,2019,76(4):418-424.
doi: 10.1016/j.eururo.2019.05.010 |
| 8 |
MontgomeryB , TretiakovaMS , JoshuaAM ,et al.Neoadjuvant enzalutamide prior to prostatectomy[J].Clin Cancer Res,2017,23(9):2169-2176.
doi: 10.1158/1078-0432.CCR-16-1357 |
| 9 |
YangX , AllenJC , AslimEJ ,et al.Patient-reported outcomes of a phase Ⅱ neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate- to high-risk prostate cancer (NEAR) trial[J].Int J Urol,2022,29(11):1322-1330.
doi: 10.1111/iju.14994 |
| 10 |
DevosG , ToscoL , BaldewijnsM ,et al.ARNEO: A randomized phase Ⅱ trial of neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer[J].Eur Urol,2023,83(6):508-518.
doi: 10.1016/j.eururo.2022.09.009 |
| 11 |
MckayRR , YeH , XieW ,et al.Evaluation of intense androgen deprivation before prostatectomy: A randomized phase Ⅱ trial of enzalutamide and leuprolide with or without abiraterone[J].J Clin Oncol,2019,37(11):923-931.
doi: 10.1200/JCO.18.01777 |
| 12 |
EfstathiouE , BoukovalaM , SpetsierisN ,et al.Neoadjuvant apalutamide (APA) plus leuprolide (LHRHa) with or without abiraterone (AA) in localized high-risk prostate cancer (LHRPC)[J].J Clin Oncol,2020,38,5504.
doi: 10.1200/JCO.2020.38.15_suppl.5504 |
| 13 |
MckayRR , XieW , YeH ,et al.Results of a randomized phase Ⅱ trial of intense androgen deprivation therapy prior to radical prostatectomy in men with high-risk localized prostate cancer[J].J Urol,2021,206(1):80-87.
doi: 10.1097/JU.0000000000001702 |
| 14 |
SweeneyCJ , ChenYH , CarducciM ,et al.Chemohormonal therapy in metastatic hormone-sensitive prostate cancer[J].N Engl J Med,2015,373(8):737-746.
doi: 10.1056/NEJMoa1503747 |
| 15 |
JamesND , SydesMR , ClarkeNW ,et al.Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial[J].Lancet,2016,387(10024):1163-1177.
doi: 10.1016/S0140-6736(15)01037-5 |
| 16 |
PanJ , ChiC , QianH ,et al.Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study[J].Urol Oncol,2019,37(12):991-998.
doi: 10.1016/j.urolonc.2019.07.009 |
| 17 |
DreicerR , Magi-GalluzziC , ZhouM ,et al.Phase Ⅱ trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate can-cer[J].Urology,2004,63(6):1138-1142.
doi: 10.1016/j.urology.2004.01.040 |
| 18 | MikkilineniN , HyamsES .Neoadjuvant therapies for surgical management of high-risk, localized prostate cancer[J].Transl Cancer Res,2018,7(Suppl 6):S662-S675. |
| 19 |
FizaziK , FaivreL , LesaunierF ,et al.Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): A phase 3 randomised controlled trial[J].Lancet Oncol,2015,16(7):787-794.
doi: 10.1016/S1470-2045(15)00011-X |
| 20 |
潘家骅, 刘家舟, 王勇,等.新辅助内分泌治疗联合化疗对极高危局部进展期前列腺癌疗效的多中心临床分析[J].中华泌尿外科杂志,2021,42(9):685-690.
doi: 10.3760/cma.j.cn112330-20210819-00436 |
| 21 |
GlicksmanR , SanmamedN , ThomsJ ,et al.A phase 1 pilot study of preoperative radiation therapy for prostate cancer: Long-term toxicity and oncologic outcomes[J].Int J Radiat Oncol Biol Phys,2019,104(1):61-66.
doi: 10.1016/j.ijrobp.2018.12.054 |
| 22 |
SartorO , de BonoJ , ChiKN ,et al.Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer[J].N Engl J Med,2021,385(12):1091-1103.
doi: 10.1056/NEJMoa2107322 |
| 23 |
GolanS , FrumerM , ZoharY ,et al.Neoadjuvant 177Lu-PSMA-I&T radionuclide treatment in patients with high-risk prostate cancer before radical prostatectomy: A single-arm phase 1 trial[J].Eur Urol Oncol,2023,6(2):151-159.
doi: 10.1016/j.euo.2022.09.002 |
| 24 | HanksGE .External-beam radiation therapy for clinically localized prostate cancer: Patterns of care studies in the United States[J].NCI Monogr,1988,(7):75-84. |
| 25 |
AusG , NordenskjoldK , RobinsonD ,et al.Prognostic factors and survival in node-positive (N1) prostate cancer: A prospective study based on data from a Swedish population-based cohort[J].Eur Urol,2003,43(6):627-631.
doi: 10.1016/S0302-2838(03)00156-8 |
| 26 |
PassoniNM , FajkovicH , XylinasE ,et al.Prognosis of patients with pelvic lymph node (LN) metastasis after radical prostatectomy: Value of extranodal extension and size of the largest LN metastasis[J].BJU Int,2014,114(4):503-510.
doi: 10.1111/bju.12342 |
| 27 | DaneshmandS , QuekML , SteinJP ,et al.Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: Long-term results[J].J Urol,2004,172(6 Pt 1):2252-2255. |
| 28 |
WiegelT , BartkowiakD , BottkeD ,et al.Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial[J].Eur Urol,2014,66(2):243-250.
doi: 10.1016/j.eururo.2014.03.011 |
| 29 |
ThompsonIM , TangenCM , ParadeloJ ,et al.Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: Long-term followup of a randomized clinical trial[J].J Urol,2009,181(3):956-962.
doi: 10.1016/j.juro.2008.11.032 |
| 30 |
BollaM , van PoppelH , TombalB ,et al.Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: Long-term results of a randomised controlled trial (EORTC trial 22911)[J].Lancet,2012,380(9858):2018-2027.
doi: 10.1016/S0140-6736(12)61253-7 |
| 31 |
HackmanG , TaariK , TammelaTL ,et al.Randomised trial of adjuvant radiotherapy following radical prostatectomy versus radical prostatectomy alone in prostate cancer patients with positive margins or extracapsular extension[J].Eur Urol,2019,76(5):586-595.
doi: 10.1016/j.eururo.2019.07.001 |
| 32 |
GhavamianR , BergstralhEJ , BluteML ,et al.Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: A matched comparison[J].J Urol,1999,161(4):1223-1227.
doi: 10.1016/S0022-5347(01)61640-9 |
| 33 |
MessingEM , ManolaJ , YaoJ ,et al.Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy[J].Lancet Oncol,2006,7(6):472-479.
doi: 10.1016/S1470-2045(06)70700-8 |
| 34 |
AbdollahF , KarnesRJ , SuardiN ,et al.Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer[J].J Clin Oncol,2014,32(35):3939-3947.
doi: 10.1200/JCO.2013.54.7893 |
| 35 |
LowranceW , DreicerR , JarrardDF ,et al.Updates to advanced prostate cancer: AUA/SUO guideline (2023)[J].J Urol,2023,209(6):1082-1090.
doi: 10.1097/JU.0000000000003452 |
| 36 |
RoachPJ , FrancisR , EmmettL ,et al.The impact of 68Ga-PSMA PET/CT on management intent in prostate cancer: Results of an Australian prospective multicenter study[J].J Nucl Med,2018,59(1):82-88.
doi: 10.2967/jnumed.117.197160 |
| 37 |
YaxleyJW , RaveenthiranS , NouhaudF X ,et al.Risk of metastatic disease on 68gallium-prostate-specific membrane antigen positron emission tomography/computed tomography scan for primary staging of 1 253 men at the diagnosis of prostate cancer[J].BJU Int,2019,124(3):401-407.
doi: 10.1111/bju.14828 |
| 38 |
HofmanMS , LawrentschukN , FrancisRJ ,et al.Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomised, multicentre study[J].Lancet,2020,395(10231):1208-1216.
doi: 10.1016/S0140-6736(20)30314-7 |
| [1] | 李志存, 吴天俣, 梁磊, 范宇, 孟一森, 张骞. 穿刺活检单针阳性前列腺癌术后病理升级的危险因素分析及列线图模型构建[J]. 北京大学学报（医学版）, 2024, 56(5): 896-901. |
| [2] | 田宇轩,阮明健,刘毅,李德润,吴静云,沈棋,范宇,金杰. 双参数MRI改良PI-RADS评分4分和5分病灶的最大径对临床有意义前列腺癌的预测效果[J]. 北京大学学报（医学版）, 2024, 56(4): 567-574. |
| [3] | 姚凯烽,阮明健,李德润,田宇轩,陈宇珂,范宇,刘毅. 靶向穿刺联合区域系统穿刺对PI-RADS 4~5分患者的前列腺癌诊断效能[J]. 北京大学学报（医学版）, 2024, 56(4): 575-581. |
| [4] | 欧俊永,倪坤明,马潞林,王国良,颜野,杨斌,李庚午,宋昊东,陆敏,叶剑飞,张树栋. 肌层浸润性膀胱癌合并中高危前列腺癌患者的预后因素[J]. 北京大学学报（医学版）, 2024, 56(4): 582-588. |
| [5] | 李文菁,张保宙,李恒,赖良鹏,杜辉,孙宁,龚晓峰,李莹,王岩,武勇. 胫距跟融合治疗终末期踝和后足病变的中短期临床结果[J]. 北京大学学报（医学版）, 2024, 56(2): 299-306. |
| [6] | 邹雪,白小娟,张丽卿. 艾拉莫德联合托法替布治疗难治性中重度类风湿关节炎的疗效[J]. 北京大学学报（医学版）, 2023, 55(6): 1013-1021. |
| [7] | 刘毅,袁昌巍,吴静云,沈棋,肖江喜,赵峥,王霄英,李学松,何志嵩,周利群. 靶向穿刺+6针系统穿刺对PI-RADS 5分患者的前列腺癌诊断效能[J]. 北京大学学报（医学版）, 2023, 55(5): 812-817. |
| [8] | 毛海,张帆,张展奕,颜野,郝一昌,黄毅,马潞林,褚红玲,张树栋. 基于MRI前列腺腺体相关参数构建腹腔镜前列腺癌术后尿失禁的预测模型[J]. 北京大学学报（医学版）, 2023, 55(5): 818-824. |
| [9] | 邱敏,宗有龙,王滨帅,杨斌,徐楚潇,孙争辉,陆敏,赵磊,卢剑,刘承,田晓军,马潞林. 腹腔镜肾部分切除术治疗中高复杂程度肾肿瘤的效果[J]. 北京大学学报（医学版）, 2023, 55(5): 833-837. |
| [10] | 袁昌巍,李德润,李志华,刘毅,山刚志,李学松,周利群. 多参数磁共振成像中动态对比增强状态在诊断PI-RADS 4分前列腺癌中的应用[J]. 北京大学学报（医学版）, 2023, 55(5): 838-842. |
| [11] | 王磊,韩天栋,江卫星,李钧,张道新,田野. 主动迁移技术与原位碎石技术在输尿管软镜治疗1~2 cm输尿管上段结石中的安全性和有效性比较[J]. 北京大学学报（医学版）, 2023, 55(3): 553-557. |
| [12] | 李伟浩,李伟,张学民,李清乐,焦洋,张韬,蒋京军,张小明. 去分支杂交手术和传统手术治疗胸腹主动脉瘤的结果比较[J]. 北京大学学报（医学版）, 2022, 54(1): 177-181. |
| [13] | 朱正达,高岩,何汶秀,方鑫,刘洋,魏攀,闫志敏,华红. 红色诺卡氏菌细胞壁骨架治疗糜烂型口腔扁平苔藓的疗效及安全性[J]. 北京大学学报（医学版）, 2021, 53(5): 964-969. |
| [14] | 刘毅,刘志坚,沈棋,吴静云,范宇,李德润,虞巍,何志嵩. 14例恶性潜能未定的前列腺间质肿瘤病例分析[J]. 北京大学学报（医学版）, 2020, 52(4): 621-624. |
| [15] | 郝一昌,颜野,张帆,邱敏,周朗,刘可,卢剑,肖春雷,黄毅,刘承,马潞林. 穿刺活检单针阳性的前列腺癌手术策略选择及经验总结[J]. 北京大学学报（医学版）, 2020, 52(4): 625-631. |
|
||
